Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Timothy P. Hughes1,*, Jeffrey H. Lipton2, Nelson Spector3, Francisco Cervantes4, Ricardo Pasquini5, Nelma Cristina D. Clementino6, Pedro Enrique Dorlhiac Llacer7, Anthony P. Schwarer8, Francois-Xavier Mahon9, Delphine Rea10, Susan Branford11, Das Purkayastha12, LaTonya Collins12, Tomasz Szczudlo12, and Brian Leber13

Hughes1,*, Jeffrey H. Lipton2, Nelson Spector3, Francisco Cervantes4, Ricardo Pasquini5, Nelma Cristina D. Clementino6, Pedro Enrique Dorlhiac Llacer7, Anthony P. Schwarer8, Francois-Xavier Mahon9, Delphine Rea10, Susan Branford11, Das Purkayastha12, LaTonya Collins12, Tomasz Szczudlo12, and Brian Leber13

Key Points
* Nilotinib induced deeper molecular responses than continued imatinib in patients with minimal residual disease on long-term imatinib.
* These deeper responses may enable more patients to benefit from treatment-free remission trials.

http://bloodjournal.hematologylibrary.org/content/early/2014/06/19/blood...

You are here

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib